4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

AIM: Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability. In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Clin Pharmacol
Autori principali: de Graan, Anne-Joy M, Sparreboom, Alex, de Bruijn, Peter, de Jonge, Evert, van der Holt, Bronno, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, van Schaik, Ron H N
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Ltd 2015
Soggetti:
Pharmacokinetics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4574840/
https://ncbi.nlm.nih.gov/pubmed/26119961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12707
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi